Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20683460 | 0.77 | — | — | |
| SCHEMBL24474695 | 0.75 | — | — | |
| SCHEMBL1106850 | 0.71 | ANPEP (0.33) | ANPEPLAP3APLNR | |
| SCHEMBL12571463 | 0.69 | ANPEP (0.32) | ANPEPLAP3APLNR | |
| SCHEMBL13857694 | 0.69 | ANPEP (0.32) | ANPEPLAP3APLNR | |
| SCHEMBL1691193 | 0.69 | ANPEP (0.32) | ANPEPLAP3APLNR | |
| SCHEMBL12991901 | 0.69 | ANPEP (0.38) | ANPEPLAP3APLNR | |
| Hydrochloric Acid SCHEMBL20515123 | 0.67 | ANPEP (0.36) | ANPEPLAP3 | |
| SCHEMBL23969676 | 0.67 | ANPEP (0.31) | ANPEPLAP3 | |
| SCHEMBL12344531 | 0.67 | ANPEP (0.31) | ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081864-A | Synthesis method of 1, 3-diboron compound | 西安交通大学 | 2025-06-03 | — | — | CN | claimed |
| US-20240051976-A1 | A Tracer Compound and a Preparation Method Thereof | TURUN YLIOPISTO (FI) | 2024-02-15 | — | — | US | claimed |
| EP-4267589-A1 | A TRACER COMPOUND AND A PREPARATION METHOD THEREOF | Turun yliopisto (FI) | 2023-11-01 | — | — | EP | claimed |
| CN-116829195-A | Tracer compound and preparation method thereof | 图尔库大学 | 2023-09-29 | — | — | CN | claimed |
| WO-2022144501-A1 | A TRACER COMPOUND AND A PREPARATION METHOD THEREOF | TURUN YLIOPISTO (FI) | 2022-07-07 | — | — | WO | claimed |
| US-20100056615-A1 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSM IP ASSETS B.V. (NL) | 2010-03-04 | — | — | US | claimed |
| EP-2083805-A2 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSMIP Assets B.V. (NL) | 2009-08-05 | — | — | EP | claimed |
| WO-2008061720-A2 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSM IP ASSETS B.V. (NL) | 2008-05-29 | — | — | WO | claimed |
| EP-1925301-A1 | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | DSMIP Assets B.V. (NL) | 2008-05-28 | — | — | EP | claimed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| US-12590108-B2 | Boracic acid compound | PHAENO THERAPEUTICS CO., LTD (CN) | 2026-03-31 | — | — | US | disclosed |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-11-18 | — | — | US | disclosed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-09-30 | — | — | US | disclosed |
| WO-2008061720-A2 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | DSM IP ASSETS B.V. (NL) | 2008-05-29 | — | — | WO | disclosed |
| EP-1925301-A1 | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | DSMIP Assets B.V. (NL) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925301-A1 | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders | DSMIP Assets B.V. (NL) | 2008-05-28 | — | — | EP | disclosed |
| JP-2003259891-A | METHOD FOR PRODUCING DEHYDROABIETIC ACID DERIVATIVE | UNIV NIHON | 2003-09-16 | — | — | JP | disclosed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | TFRC, SLC39A3, SLC39A14 | ANPEP 1454/4885LAP3 337/4885APLNR 1564/4885 |
| US-12590108-B2 | Boracic acid compound | ME1, GPBAR1, BCL6 | ANPEP 4444/4885LAP3 2816/4885APLNR 3892/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | ANPEP 385/4885LAP3 1012/4885APLNR 65/4885 |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | KLK3, FOLH1, HRH3 | ANPEP 1234/4885LAP3 407/4885APLNR 1900/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | ANPEP 699/4885LAP3 1446/4885APLNR 1422/4885 |
| US-20100056615-A1 | USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS | TNF, VDR, CYP24A1 | ANPEP 3597/4885LAP3 4020/4885APLNR 2955/4885 |
| US-20240051976-A1 | A Tracer Compound and a Preparation Method Thereof | TALDO1, SLCO2B1, SLCO1B1 | ANPEP 963/4885LAP3 1052/4885APLNR 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.